Collaborating to Conquer Cancer

Annual Meeting ’12

www.asco.org

Program
„Best of ASCO® Slovakia 2012“

Best of ASCO® Meeting
Licensed by the American Society of Clinical Oncology

4. ročník / 4th Annual

20. October 2012 | Holiday Inn, Bratislava, Slovakia
Breast Cancer Session
Chairmen: Mária Wagnerová, Stanislav Špánik

08.35 – 09.05
1. Breast Cancer – (Ahmad Awada, Jules Bordet Instituut Brussel)
   1. Abstract #LBA1: Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (Kimberly L. Blackwell)
   2. Abstract #LBA671: Randomized Controlled Trial Comparing Taxane-Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2+ Metastatic Breast Cancer: Interim Analysis of NCIC CTG MA.31/ GSK EGF 108919. (K Gelmon)
   3. Abstract #1002: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). (Hope S. Rugo)
   5. Abstract # 1023: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. (Gunter Von Minckwitz)

09.05 – 09.35
2. Breast Cancer – (Juraj Beniak, POKO Poprad)
   1. Abstract # 501: Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. (Lois E. Shepherd)
   2. Abstract # 502: Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): Treatment effects are influenced by menopausal status rather than age. (Helen Marshall)
   3. Abstract # 1004: RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). (Beryl McCormick)
4. Abstract # LBA1000: NSABP B-38: Definitive analysis of patient outcome from a randomized trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (Sandra M. Swain)

09.35 – 10.05 Discussion

10.05 – 10.25 Coffee Break

Lung Cancer and Patient & Survivor Care Session
Chairmen: Peter Kasan, Vladimír Malec (10.25 – 11.55)

10.25 – 10.55

1. Lung Cancer (Peter Beržinec, ŠN sv. Svorada Zobor, Nitra)
   1. Abstract # 7000: Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature. (Satomi Yamamoto)
   2. Abstract # 7004: Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer. (Keunchil Park)
   3. Abstract # 7008: Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial. (Eric L Grogan)
   4. Abstract # 7506: A randomized phase III trial of single agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. (Rogerio Lilenbaum)
   5. Abstract # LBA 7500: LUX-lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. (James Chih-Hsin Yang)
   6. Abstract # LBA 7501: TAILOR: Phase III trial comparison of erlotinib versus docetaxel in the second-line treatment of wild type (wt) EGFR patients with NSCLC. (Marina Chiara Garassino)
   7. Abstract # 7508: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. (Alice Tsang Shaw)
2. **Patient & Survivor Care** (Andrea Škripeková, NOÚ Bratislava)
   1. Abstract # 9013: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN). (Ellen M. Lavoie Smith)
   2. Abstract # 9000: Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms and fatigue in women with breast cancer starting adjuvant letrozole: The VITAL trial. (Qamar J. Khan)
   3. Abstract # 9003: Cluster-randomized trial of early palliative care for patients with metastatic cancer. (Camilla Zimmermann)
   4. Abstract # 9005: ZOOM: A prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1 yr of standard ZOL treatment. (Dino Amadori)
   5. Abstract # 9001: Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2. (Debra L. Barton)

11.25 – 11.55 Discussion

11.55 – 13.30 Lunch

**Genitourinary Cancer and Gynecologic Cancer Session**

*Chairmen: Jozef Mardiak, Tibor Packaň*

13.30 – 15.00

5. **Genitourinary Cancer** (Michal Mego, NOÚ Bratislava)
   1. Abstract # 4501: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. (Robert John Motzer)
   2. Abstract # 4: Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. (Maha Hussain)
   3. Abstract # 4519: Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (Johann Sebastian De Bono)
   4. Abstract # 4518: Interim analysis results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). (Charles J. Ryan)
   5. Abstract # 4512: Final overall survival analysis results from the phase III, double-blind, randomized, multinational study of radium-223 chloride in the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases (ALSYMPCA). (Chris Parker)
6. Gynecologic Cancer (Seamus O’Reilly, Cork-Mercy&South Infirmary Victoria University Hospital)

1. Abstract # 5006: A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). (Ryo Kitagawa)

2. Abstract # 5004: Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. (Noriyuki Katsumata)


4. Abstract # LBA 5002: AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) combined with chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC). (Eric Pujade-Lauraine)

7. Head&Neck Cancer, CNS Tumors (Richard Hrubý, FNsP Žilina)

1. Abstract # 5500: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). (Ezra E.W. Cohen)

2. Abstract # 5501: The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). (Robert I. Haddad)

3. Abstract # 5502: A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (Jordi Giralt)

4. Abstract # 5508: An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. (Patrick Schoffski)

5. Abstract # 2: Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendrogial tumors (AOD). (Martin J. Van Den Ben)

8. Melanoma, Sarcoma (Zuzana Hlavatá, NOÚ Bratislava)
1. Abstract # LBA 8500: BREAK 3: A randomized, phase III, open-label, multicenter trial comparing the selective BRAF kinase-inhibitor dabrafenib (GSK2118436) with dacarbazine in treatment-naive, unresectable or metastatic melanoma patients with BRAFV600E mutation. (Axel Hauschild)
2. Abstract # 8501: BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). (John M. Kirkwood)
3. Abstract # 8509: METRIC: A phase III randomized, open-label study comparing trametinib (GSK1120212) to chemotherapy (CT) in CT-naive or pre-treated patients with advanced or metastatic BRAFV600E/k mutation-positive melanoma. (Caroline Robert)
5. Abstract # 8504: Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG. (Lawrence E. Flaherty)
6. Abstract # LBA10008: Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. (George D. Demetri)

16.00 – 16.30 Discussion

16.30 – 17.00 Coffee Break

Gastrointestinal Cancer Session
Chairmen: Tomáš Šálek, Jozef Chovanec

17.00 – 17.30
9. Gastrointestinal (Non-Colorectal) Cancer (Mária Višňovská, VOÚ Košice)
1. Abstract # LBA 4003: Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. (Thierry Conroy)
2. Abstract # LBA 4000: A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab in previously untreated advanced esophagogastric cancer (REAL3). (Tom Samuel Waddell)
3. Abstract # 4004: Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. (Robert Glynne-Jones)
4. Abstract # 4008: A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. (Zhenggang Ren)
17.30 – 18.00 10. Gastrointestinal cancer (Colorectal) (Vanda Ušáková, OÚSA Bratislava)
1. Abstract # 3505: Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. (Carmen Joseph Allegra)
2. Abstract # LBA 3500: Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer: Efficacy results of the international GERCOR DREAM phase III trial. (Christophe Tournigand)
3. Abstract # CRA 3503: Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). (Dirk Arnold)
4. Abstract #3502: Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). (Eric Van Cutsem)
5. Abstract # LBA 3501: Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). (Johanna C. Bendell)
6. Abstract # 3508: EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. (Bernard Nordlinger)

18:00 – 18:30 Discussion

18.30 – 18.35 FAREWELL

Predsedajúci, prednášajúci / Faculty
doc. MUDr. Igor Andrašina, CSc., VOÚ, Košice, Slovakia
Ahmad Awada, MD, PhD. Jules Bordet Instituut, Brussel, Belgium
MUDr. Juraj Beniak, POKO Poprad, Slovakia
doc. MUDr. Peter Beržinec, CSc., ŠN sv. Svorada Zobor, Nitra, Slovakia
MUDr. Zuzana Hlavatá, NOÚ, Bratislava, Slovakia
MUDr. Richard Hrubý, PhD., FNsP Žilina, Slovakia
MUDr. Jozef Chovanec, POKO sv. Jakuba, Bardejov, Slovakia
MUDr. Peter Kasan, Univerzitná nemocnica Ružinov, Bratislava, Slovakia
MUDr. Vladimir Malec, NsP FDR, Banská Bystrica, Slovakia
doc. MUDr. Jozef Mardiak, CSc., NOÚ, Bratislava, Slovakia
doc. MUDr. Michal Mego, PhD., NOÚ, Bratislava, Slovakia
Seamus O'Reilly, BSc MD PhD FRCPI Cork-Mercy & South Infirmary Victoria University Hospital, Cork, Ireland
MUDr. Tibor Packaň, PhD., VOÚ, Košice, Slovakia
MUDr. Dagmar Sorkovská, OÚSA, Bratislava, Slovakia
MUDr. Tomáš Šálek, NOÚ, Bratislava, Slovakia
MUDr. Andrea Škripeková, NOÚ, Bratislava, Slovakia
prof. MUDr. Stanislav Španík, CSc., NOÚ, Bratislava, Slovakia
MUDr. Vanda Ušáková, OÚSA, Bratislava, Slovakia
MUDr. Mária Višňovská, VOÚ, Košice, Slovakia
doc. MUDr. Mária Wagnerová, CSc., VOÚ, Košice, Slovakia
prof. MUDr. Stanislav Špánik, CSc., NOÚ, Bratislava, Slovakia
MUDr. Vanda Ušáková, OÚSA, Bratislava, Slovakia
MUDr. Mária Višňovská, VOÚ, Košice, Slovakia

doc. MUDr. Mária Wagnerová, CSc., VOÚ, Košice, Slovakia

Organizačné zabezpečenie/ Organizational Management
SOLEN, s. r. o., Lovinského 16, 811 04 Bratislava, kongres@solen.sk. www.solen.sk

Podujatie bude ohodnotené 8 CME kreditmi / The attendees will receive 8 CME credits.
Priezvisko, meno, titul
Surname, Name, Title

adresa pracoviska:
Work Address:

Tel., fax:                                        e-mail:

Reg. č. Slovenskej lekárskej komor
Reg. Number of the slovak medical chamber:

Záväzná objednávka ubytovania v Hoteli holiday inn
/Obligatory order of the accomodation in the Holiday inn (To 5.10.2012)

Na základe vyplneného formulára Vám bude obratom zaslaná zálohová faktúra na ubytovanie.
(The deadline for application is 5th of October 2012 (accommodation) or 12th of October 2012 (attendance).)

I would like to book a room:

□ Yes            □ No

Je mi záujem o ubytovanie z 19. na 20. 10. 2012
I would like to book a room from 19th till 20th of October 2012

□ changes are possible without any fees until 5th of October 2012. After 5th of October 2012, there will be charged a 100% cancellation fee.

□ I would like to share a room with:

□ I would like to book an individual room at the reception.

□ I hereby give permission to the SOLEN Company for the usage of my personal data that is presented in this document, for the purpose of the processing of application forms and for the distribution of informational emails according to the act No. 428/2002. The act No. 482/2002 deals with security of personal data. This permission may be cancelled anytime in writing.

Please, send completed Application Form to the address of the organizer by mail, email or fax (+421 2 5465 1384).

Organizátor: SOLEN, s. r. o., Lovinského 16, 811 04 Bratislava, e-mail: kongres@solen.sk